对用于他莫昔芬治疗的乳腺癌患者CYP2D6表型分析的¹³C-右美沙芬呼气试验的进一步表征。

Further characterization of a ¹³C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy.

作者信息

Opdam F L, Modak A S, Gelderblom H, Guchelaar H J

机构信息

Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

J Breath Res. 2015 Apr 20;9(2):026003. doi: 10.1088/1752-7155/9/2/026003.

DOI:10.1088/1752-7155/9/2/026003

PMID:25891764

Abstract

In a previous study, we found that the CYP2D6 phenotype determined by (13)C-dextromethorphan breath test (DM-BT) might be used to predict tamoxifen treatment outcome in breast cancer patients in the adjuvant setting. However, large variation in the delta-over-baseline (DOB) values was observed in the extensive metabolizer predicted phenotype group based on single point measures. In the present work we aimed to analyze the variability of phenotype results and determine reproducibility to further characterize the clinical utility of DM-BT by introducing multiple breath sampling instead of single breath sampling and by administration of a fixed dose of (13)C-DM.

摘要

在之前的一项研究中，我们发现，通过（13）C-右美沙芬呼气试验（DM-BT）确定的CYP2D6表型可能用于预测辅助治疗环境下乳腺癌患者的他莫昔芬治疗效果。然而，在基于单点测量预测的广泛代谢者表型组中，观察到基线差值（DOB）值存在较大差异。在本研究中，我们旨在分析表型结果的变异性并确定可重复性，以通过引入多次呼气采样而非单次呼气采样以及给予固定剂量的（13）C-DM来进一步表征DM-BT的临床效用。